We are a 100% all-volunteer 501(c)(3) non-profit charity. No one takes a paycheck here and there are no administrative costs. That means 100% of all funds raised by the R.A.S.C.A.L.S. Foundation go directly to fighting ALS.
The money goes to fund promising treatment research and development. It helps with ALS family assistance, such as our annual Higher Education Scholarship program.
April marks National Volunteer Month. This observance holds very special meaning for all of us here at the Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.). That’s because we are a 100% all-volunteer 501(c)(3) non-profit charity. There are no administrative costs.
That means no salaries, payments, or perks for anyone. Out-of-pocket expenses truly means out of our [...]
Researchers at Emory University School of Medicine have demonstrated that this ALS/FTD mutation may be harmful because it creates an “RNA sponge,” soaking up an important regulatory protein that binds RNA.
Cytokinetics, Incorporated announced today the initiation of a first-time-in-humans, Phase I clinical trial of CK-2127107 in healthy male volunteers. Cytokinetics is developing CK-2127107, a novel small molecule activator of the fast skeletal muscle troponin complex, for the potential improvement of skeletal muscle function in diseases and medical conditions associated with neuromuscular dysfunction, muscular weakness, and/or muscle fatigue. Like tirasemtiv, the lead drug candidate from the company’s skeletal muscle activator program, CK-2127107 slows the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium.
Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function
NEW YORK, NY and PETACH TIKVAH, ISRAEL, March 21, 2013 — BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company’s NurOwn™ technology in 12 ALS patients. NurOwn [...]
“This innovative diaphragm pacing system is an exciting development in the treatment of ALS. It has the potential to improve and extend the lives of hundreds of ALS patients. It is thrilling that our BWH team is able to bring this new treatment to ALS patients in New England,” said Dr. Ducko.
At a time when scientists are making rapid gains in the genetic roots of many diseases, Mr. Doctoroff, a former deputy mayor and private equity investor, is working with Mayor Michael R. Bloomberg and a private equity director, David M. Rubenstein, to put together a $25 million package of donations to support research to try to cure this rare and usually fatal degenerative neurological illness.
Daniel L. Doctoroff, chief executive officer and president of Bloomberg LP; David M. Rubenstein, co-CEO of The Carlyle Group; and Bloomberg Philanthropies said Target ALS is a $25 million three-year initiative to tackle ALS in a different way.
“In identifying the novel protein that abnormally accumulates in the brains of affected patients, we have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases,” says senior author Dr. Leonard Petrucelli, Chair of Neuroscience at Mayo Clinic in Florida.
In work supported by The ALS Association and funded through The Milton Safenowitz Post-Doctoral Fellowship Program, researchers have for the first time reprogrammed a neuron from one type into another and have done so in a living organism. The finding will help scientists better understand how to control neuronal development and may one day aid in treating diseases in which neurons die, such as amyotrophic lateral sclerosis (ALS). The study was published in the journal Nature Cell Biology.